Abstract:Accumulating evidences revealed that long noncoding RNAs (lncRNAs) have been participated in cancer malignant progression, including glioblastoma multiforme (GBM). Despite much studies have found the precise biological role in the regulatory mechanisms of GBM, however the molecular mechanisms, particularly upstream mechanisms still need further elucidated. RT-QPCR, cell transfection, western blotting and bioinformatic analysis were executed to detect the expression of EGR1, HNF1A-AS1, miR-22-3p and ENO1 in GBM. Cell proliferation assay, colony formation assay, wound healing, migration and invasion assays were performed to detect the malignant characters of GBM cells. The molecular regulation mechanism was confirmed by luciferase reporter assay, ChIP and RIP. Finally, orthotopic mouse models were established to examine the effect of HNF1A-AS1 in vivo. In the current study, we analyzed clinical samples to show that the HNF1A-AS1 expression is upregulated and associated with poor patient survival in GBM. Functional studies revealed that HNF1A-AS1 knockdown markedly inhibits malignant phenotypes of GBM cells, whereas overexpression of HNF1A-AS1 exerts opposite effect. Mechanistically, the transcription factor EGR1 forced the HNF1A-AS1 expression by directly binding the promoter region of HNF1A-AS1. Furthermore, combined bioinformatics analysis with our mechanistic work, using luciferase reporter assays and RIP, we first demonstrated that HNF1A-AS1 functions as a competing endogenous RNA (ceRNA) with miR-22-3p to regulate ENO1 expression in GBM cells. HNF1A-AS1 directly binds to miR-22-3p and significantly inhibits miR-22-3p expression, while ENO1 expression was increased. miR-22-3p inhibitor offsets the HNF1A-AS1 silencing induced suppression in malignant behaviors of GBM cells. ENO1 was verified as a direct target of miR-22-3p and its expression levels was negatively with the prognosis in GBM patients. Taken together, our study illuminated the definite mechanism of HNF1A-AS1 in promoting GBM malignancy, and provided a novel therapeutic target for further clinical application.

lncRNA H19 binds VGF and promotes pNEN progression via PI3K/AKT/CREB signaling

Long Non‑coding RNA PVT1 Promotes Epithelial‑mesenchymal Transition Via the TGF‑β/Smad Pathway in Pancreatic Cancer Cells.

EGFR is a Potential Therapeutic Target for Highly Glycosylated and Aggressive Pancreatic Neuroendocrine Neoplasms.

Long non-coding RNA H19, a novel therapeutic target for pancreatic cancer

The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma.

lncRNA H19 promotes glioblastoma multiforme development by activating autophagy by sponging miR-491-5p

EGR1 Modulated LncRNA HNF1A-AS1 Drives Glioblastoma Progression Via Mir-22-3p/eno1 Axis

Transcriptional Profiling Reveals the Regulatory Role of DNER in Promoting Pancreatic Neuroendocrine Neoplasms

H19 encourages aerobic glycolysis and cell growth in gastric cancer cells through the axis of microRNA-19a-3p and phosphoglycerate kinase 1

Long Noncoding RNA RP11-732M18.3 Promotes Glioma Angiogenesis by Upregulating VEGFA

LINC00941 Promotes Progression of Non-Small Cell Lung Cancer by Sponging miR-877-3p to Regulate VEGFA Expression

Expression and prognostic value of long non-coding RNA H19 in glioma via integrated bioinformatics analyses

LncRNA H19 Promotes Cell Proliferation, Migration, and Angiogenesis of Glioma by Regulating Wnt5a/β-Catenin Pathway via Targeting miR-342

Long Non-Coding RNA H19 Regulates FOXM1 Expression by Competitively Binding Endogenous Mir-342-3p in Gallbladder Cancer

LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer

H19-and hsa-miR-338-3p-mediated NRP1 expression is an independent predictor of poor prognosis in glioblastoma

Long Noncoding RNA PVT1 Indicates a Poor Prognosis of Gastric Cancer and Promotes Cell Proliferation Through Epigenetically Regulating P15 and P16

LncRNA H19-Derived miR-675-3p Promotes Epithelial-Mesenchymal Transition and Stemness in Human Pancreatic Cancer Cells by targeting the STAT3 Pathway.

Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer

H19 promotes polarization and alternative splicing in tumor-associated macrophages, facilitating pancreatic cancer progression

A Positive Feedback Loop of Lncrna-Pvt1 and FOXM1 Facilitates Gastric Cancer Growth and Invasion.